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ABSTRACT
Long noncoding RNAs (lncRNAs) are non-proten-coding transcripts of more 
than 200 nucleotides generated by RNA polymerase II and their expressions are 
tightly regulated in cell type specific- and/or cellular differential stage specific- 
manner. MIAT, originally isolated as a candidate gene for myocardial infarction, 
encodes lncRNA (termed MIAT). Here, we determined the expression level of MIAT 
in established leukemia/lymphoma cell lines and found its upregulation in lymphoid 
but not in myeloid cell lineage with mature B cell phenotype. MIAT expression level 
was further determined in chronic lymphocytic leukemias (CLL), characterized by 
expansion of leukemic cells with mature B phenotype, to demonstrate relatively 
high occurrence of MIAT upregulation in aggressive form of CLL carrying either 
17p-deletion, 11q-deletion, or Trisomy 12 over indolent form carrying 13p-deletion. 
Furthermore, we show that MIAT constitutes a regulatory loop with OCT4 in malignant 
mature B cell, as was previously reported in mouse pulripotent stem cell, and that 
both molecules are essential for cell survival.
INTRODUCTION
Recently developed technology of next generation 
sequencing revealed that the majority of the human 
genome is transcribed, whereas only 1.5% to 2% of the 
transcripts encode proteins [1]. In addition, the degree of 
an organism complexity better correlates with the non-
coding proportion of transcriptome than with the number 
of protein-coding genes [2]. Such findings imply an 
involvement of non-coding RNAs in eukaryotic evolution. 
Long non-coding RNAs (lncRNAs) are defined as RNA 
transcripts longer than 200 nucleotides in length. Similar to 
mRNAs, lncRNAs are transcribed by RNA polymerase II, 
are capped, contain introns and are often polyadenylated 
but they lack protein coding capacity [reviewed in ref. 
3]. Known function of lncRNA includes i) scaffolds for 
chromatin modification complexes, ii) molecular guides 
to ensure the proper localization of their binding partners, 
iii) regulators for DNA looping, iv) interferer for RNA 
transcription, splicing, translation and stability, and v) co-
activator for transcription factor [ibid]. In view of such 
multi-functional facets of lncRNAs, which encompass the 
fields of transcriptional and post-transcriptional regulation 
as well as subcellular dynamics, it is conceivable that 
dysregulation of lncRNA expression causes complex 
human diseases including human malignancies. Indeed, 
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several lncRNAs have been shown to function as an 
oncogene or tumor suppressor [reviewed in ref.4]. MIAT/
RNCR2, originally discovered as a candidate gene 
for myocardial infarction [5], is a lncRNA abundantly 
expressed in nervous system [6] and retinal tissue [7]. It 
has been shown that MIAT constitutes a unique nuclear 
structure by evading nuclear export. Because of its 
physical interaction with SF1 splicing factor, MIAT in the 
cell nucleus is supposed to be involved in RNA splicing 
and to exert a regulatory effect on gene expression [8]. 
In addition, Gomafu, the mouse homologue of MIAT, has 
been shown to bind to Oct4 gene, which enhances Oct4 
expression, and Oct4 binds to and positively regulates 
Gomafu transcription in mouse ES cells, and thus, they 
constitute a regulatory feedback loop [9]. Disruption of 
the regulatory loop by enforced suppression of Gomafu 
has been further shown to induce ES cell differentiation 
[ibid.]. These studies demonstrated a role of MIAT 
as a determinant for cell fate of neuronal, retinal, and 
embryonic stem cells [5, 7, 9]. At the moment, however, 
study of MIAT in hematopoietic cell lineage has not been 
reported yet. In the present study, we determined MIAT 
expression level quantitatively in leukemia/lymphoma 
cell lines, together covering a whole hematopoietic cell 
lineages to show MIAT up-regulation in lymphoid lineage 
with mature B phenotype including chronic lymphocytic 
leukemia (CLL) and non-Hodgkin’s lymphoma. To further 
extend this finding, we determined MIAT expression level 
in primary CLL samples. This analysis showed that MIAT 
upregulation was frequently detected in aggressive forms 
of CLL defined by chromosomal abnormalities (the order 
of occurrence of MIAT upregulation: 17p del > 11q23 
del = Trisomy 12) as compared to the MIAT expression 
level in 13p deletion. We further show that, as previously 
reported in mouse embryonic stem cells [9], MIAT in 
DLBL lymphoma cells constitutes a similar regulatory 
loop with OCT4 and in lymphoma, both MIAT and OCT4 
are essential for cell survival. Upregulation of MIAT in 
aggressive forms of CLL and its biological activity in 
mature B cell malignancy indicate that MIAT may serve 
as a potential predictor for the disease outcome and its 
involvement in proliferation of the malignant B cells.
RESULTS
MIAT expression in leukemia/lymphoma cell lines 
and primary cells of CLL
We first determined MIAT expression level in 38 
established leukemia/lymphoma cell lines including 7 
B-cell acute lymphocytic leukemias with precursor B 
phenotype (BALL), one chronic lymphocytic leukemia 
(CLL), 10 acute myeloid leukemias (AML), one chronic 
myeloid leukemia (CML), 16 non-Hodgkin’s lymphomas 
containing 8 diffuse large B cell lymphomas (DLBLs), 2 
Follicular lymphomas (FL), and 6 Burkitt lymphomas, 
and 3 T-cell ALLs. Total RNAs obtained from these cell 
lines were subjected to cDNA synthesis, followed by 
quantitative real time PCR analysis using MIAT specific 
Taqman probe. In the present study, transcript of TATA 
binding protein (TBP), which is essential for execution 
of RNA polymerase II-mediated transcription including 
Figure 1: MIAT expression in Leukemia/Lymphoma cell lines. MIAT expression was shown as percentage against expression 
level of TBP according to the following formula: 2e-(critical threshold of MIAT - critical threshold of TBP) × 100. Realtime RT-PCR was 
carried out in triplicate and standard error bar was on top. *: Diffuse Large B Cell Lymphoma. **: Follicular Lymphoma.
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lncRNA production, were determined and used as an 
authentic normalizer to show MIAT expression level 
(Figure 1). This analysis showed overall low MIAT 
expression in B-ALL and myeloid lineage leukemic 
cells. In contrast, 4 out of 8 DLBLs, 2 out of 2 FLs and 
3 out of 6 Burkitt cell lines were found to express MIAT 
at moderate to high level and among them, 2 DLBL cell 
lines, DB and CI-1 were shown to be high producer of 
MIAT. Notably, relatively high expression of MIAT, next 
to DB and CI-1 cells, was observed in a CLL cell line, 
MEC1. These results suggested that MIAT is expressed in 
malignant mature B cells but not in precursor B-ALL or in 
myeloid lineage leukemias. Based on this observation, we 
next determined MIAT expression in a total of 67 primary 
leukemic cells obtained from CLL patients, each having 
defined data of chromosomal abnormality specific for 
CLL (Figure 2). The course and outcome of CLL is highly 
heterogenous and CLLs are classified into either indolent 
or aggressive form [10]. Chromosome abnormality 
detected in CLL serves as a predictor to distinguish these 
2 clinical forms. Thus, 13q deletion is frequently found 
in indolent form whereas 17p- or 11q-deletion frequently 
associates with aggressive form [11]. As shown in Figure 
2, right most group carrying the 13q deletion showed low 
MIAT expression in average. This enabled to set up MIAT 
cut-off value as mean + standard deviation, calculated 
from 26 cases of this group (gray colored area in Figure 2). 
At this setting, percentage of MIAT upregulated cases in 
13q del, 12 trisomy, 11q del, and 17p del were 15% (4/26 
cases), 37% (6/16 cases), 37% (6/16 cases), and 55% (5/9 
cases), respectively. When the two-tailed student’s t-test 
was applied, MIAT expression in 11q del, 12 trisomy, 
and 17p del against the group carrying13p deletion was 
calculated by increase of 37% (p>0.014), 57% (p>0.002), 
and 61% (p>0.001), respectively. Next, we inspected the 
value of biomarkers known to be associated with disease 
aggressiveness including IGVH mutation, ZAP70-positive 
and CD38-positive percentage in MIAT upregulated 21 
samples (Figure 3A). This analysis showed that MIAT 
upregulation coincided with unmutated IGVH (>98%) 
whereas ZAP70- (more than 20%) or CD38- (more 
than 30%) positive cases showed less linkage to MIAT 
upregulation. Studied patients in this article included 17 
dead cases and 8 cases within this group showed MIAT 
upregulation (47%). This frequency is far less than that 
of unmutated IGVH (82%). However, when the death 
group was divided into rapid (death within 6 years after 
diagnosis, 11 cases) and laggard (death afterwards, 7 ~ 20 
years, 6 cases), MIAT-upregulated cases were exclusively 
found in the former subgroup (Figure 3B). This made a 
great contrast to the occurrence of unmutated IGVH, 
which was found in both subgroups almost evenly 
[ibid]. Thus the results showed more close association of 
upregulated MIAT with rapid death cases.
MIAT constitutes positive feedback regulatory 
loop with OCT4 and both molecules act on 
evading apoptotic cell death in malignant mature 
B cells
Current finding of MIAT upregulation in aggressive 
CLL prompted us to determine whether this lncRNA is 
directly involved in disease progression. To this end, 
we first investigated expression of OCT4, a sole known 
positive transcriptional regulator for MIAT at the moment, 
previously reported in mouse pluripotent stem cells 
[9]. Western blot detected 49kDa protein, which was 
profoundly suppressed by OCT4 knockdown (Figure 
4, right panel) and therefore identified as OCT4. This 
analysis detected OCT4 in MEC1, CI-1 and DB cells but 
not in NU-DHL-1 cells (Figure 4, left panel). Since MIAT 
expression is moderate ~ high in the first 3 cell lines but 
not in the fourth line (see Figure 1), the western result 
indicated that MIAT in malignant mature B cells positively 
regulates OCT4 expression. To corroborate this possibility, 
we next suppressed MIAT by means of transfection with 
MIAT specific siRNA. For the following studies, we 
Figure 2: MIAT expression in primary leukemic cells from CLL patients. MIAT expression was determined in patient samples, 
each having defined record of chromosome abnormality. Results were from triplicate assays. Gray colored area corresponds to the MIAT 
expression range of mean + standard deviation (50.8% +7.1%) calculated from 26 cases with 13q-deletion.
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selected DB cells of DLBL origin, which exhibited highest 
efficiency for transfection as well as lentivirus infection 
among MIAT upregulated malignant B cell lines (data 
not shown). To accomplish effective MIAT knockdown, 
siRNA transfection was repeated 3 times at an interval of 
24 hr. 24 hrs after the final transfection, manipulated cells 
were subjected to RT-PCR analysis for the quantitative 
detection of MIAT and OCT4 transcripts. Treatment with 
MIAT siRNA induced approx. 50% reduction of MIAT and 
concomitant downregulation of OCT4 (7.7% reduction, 
Figure 5A). This result indicated that MIAT in malignant 
B cells positively regulates OCT4 transcription as it does 
so in mouse ES cells. In addition, in the latter cells, it has 
been shown that OCT4 regulates MIAT expression and, 
thus, both molecules make up a positive feedback loop 
[9]. This possibility was further investigated by applying 
lentivirus-mediated transduction of OCT4 shRNA in DB 
cells. As shown in Figure 4 right panel and Figure 5B, 
western blot and real time RT-PCR analyses performed 
at post-infection 72 hrs showed effective suppression of 
OCT4 by transduction of OCT4 shRNA. Furthermore, 
we could detect concomitant downregulation of MIAT 
in OCT4 suppressed cells (16.3% reduction, Figure 5B). 
Collectively, these results showed that MIAT constitutes 
positive regulatory loop with its transcriptional regulator 
OCT4 and such molecular network is conserved between 
mouse pluripotent stem cells and human malignant 
mature B cells. During MIAT and OCT4 knockdown 
experiments, we noticed cell growth inhibition after 
suppression of MIAT or OCT4 as compared to the growth 
of control treated cells (Figure 6A and 6B, left panel). This 
indicated that loss of MIAT or OCT4 induces cell death 
of malignant mature B cells. To examine this possibility, 
we next assayed Caspase3/7, sensitive apoptotic markers, 
which enable to detect early changes towards cell death, 
in MIAT and OCT4 suppressed DB cells. This assay 
showed time-dependent increase of the caspase activity 
after MIAT suppression (Figure 6A, left). Fold increase 
against the activity determined in control treated cells 
at 24 and 48 hr after siMIAT transfection were 1.08 and 
1.339, respectively. Similar result was also obtained from 
OCT4 suppressed cells, which showed time-dependant 
increase of the activity from 1.356-fold (at 48 hr) to 1.497-
fold (at 72 hr) (Figure 6B, right). Finally, these results well 
reflected the inhibitory status in cell proliferation, shown 
by the growth curve and we concluded that MIAT and 
its transcriptional regulator OCT4 are required for cell 
survival of the malignant mature B cells.
DISCUSSION
In the present study, we showed MIAT upregulation 
in malignant mature B cells including established cell 
lines of CLL and non-Hodgkin lymphoma origin as well 
as primary leukemic cells obtained from CLL patients. 
Importantly, in the latter, MIAT upregulation was shown 
to be associated with aggressive form of CLL, defined by 
chromosome abnormalities as well as clinical outcome. 
Further study of MIAT by using larger cohort would 
provide solid data to justify whether MIAT serves as a 
Figure 3: Inter-relation of MIAT upregulation with known prognostic markers in CLL. A. Patients were divided into 7 
subgroups based on the clinical laboratory data including percentage of CD38- or ZAP70-positive cells and percentage of mutated IGVH 
cells, and the frequency of each subgroup is shown as a pie chart. Percent occurrence of MIAT upregulation in each subgroup was shown 
in the chart. B. Dead cases were divided into rapid (within 6 years after diagnosis) and laggard (thereafter, 7 ~ 20 years after diagnosis) and 
their occurrence in percent were shown as a pie chart (top). Percent occurrences of MIAT upregulation and unmutated IGVH in each group 
were shown on the bottom.
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Figure 4: Western blot detection of OCT4 in leukemia/lymphoma cell lines expressing MIAT with different abundance. 
2 independent western blot results were shown as a composite figure. In each analysis, whole cell lysates were prepared from cells specified 
on top of the panel. On right panel, DB cells infected with lentivirus harboring OCT4shRNA or shRNA control (post-infection 72 hrs) were 
analyzed.
Figure 5: MIAT constitutes positive regulatory loop with OCT4 in transcription. A. DB cells transfected with MIAT specific 
siRNA were analyzed by realtime RT-PCR for the quantitative detection of MIAT, OCT4, and TBP transcripts. Assay in biological triplicate 
was carried out post-transfection 24 hrs. *Reduced expression of the primary target (MIAT), p < 0.01. ** Concomitant downregulation of 
OCT4, p < 0.05. B. DB cells infected with OCT4shRNA lentivirus were analyzed by realtime RT-PCR. Assay in biological triplicate was 
carried out post-infection 72 hrs. * Reduced expression of the primary target (OCT4), p < 0.01. ** Concomitant downregulation of MIAT, 
p < 0.05. p-value was calculated by student t-test.
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new biomarker for disease aggressiveness of chronic 
lymphocytic leukemias. In addition, due to the limitation 
of available clinical samples, the present study was 
conducted on peripheral blood mononuclear cell (PBMC) 
preparation. An issue is the presence of non-CLL cells in 
the preparation, which may affect the result of quantitative 
RT-PCR. However, remarkable lymphocytosis found in 
the studied cases suggests it less likely that contaminated 
non-CLL cells in our PBMC preparation undermine the 
present data of MIAT expression. Enrichment of CLL 
cell population by applying sorting with CD19 and CD5 
markers would resolve this issue. 
  We showed that in malignant mature B cells, 
MIAT is regulated by OCT4, a sole known positive 
transcriptional regulator for MIAT initially discovered in 
mouse ES cells [9]. This result implied an involvement of 
OCT4 in MIAT upregulation found in malignant B cell 
lines and primary CLL cells. To support this notion, we 
found that OCT4 expression level in the established cell 
lines positively correlates with MIAT expression level (see 
Figure 4). To extend the result into primary CLL samples, 
we applied quantitative RT-PCR for the detection of OCT4 
and compared its expression level with MIAT. In this study, 
we found that OCT4 expression level was low in average 
in MIAT low group, whereas it varied a lot in MIAT high 
group (data not shown). This result indicates that MIAT 
expression in CLL is not totally dependent on OCT4. 
Known factors, which lead to lncRNA dysregulation 
in cancer, include copy number alteration due to gene 
rearrangement such as deletion and amplification, cancer-
linked single nucleotide polymorphism (SNP) occurred 
in lncRNA coding gene, epigenetic changes occurred in 
imprinted loci where lncRNA is embedded or changes of 
DNA methylation state occurred in promoter region of 
lncRNA, and transcriptional regulation via transcription 
factor such as oncoprotein MYC or tumor suppressor p53 
[reviewed in ref.4]. We note that no cancer-associated 
copy number alteration or SNP has been reported at MIAT 
locus on chromosome 22q12.1.
  We think it important in the present study that 
suppression of MIAT in malignant mature B cells resulted 
in cell apoptosis. For unknown reason, it is very difficult 
to obtain MIAT silencing with high efficiency by means 
of siRNA transfection. This was first recognized in ES 
cell study [9] and we also encountered similar difficulty. 
Among cell lines DB, CI-1 and MEC1, we could obtain 
approx. 50% reduction of MIAT after repetition of 
transfection (3 times) only in DB cells. This limited our 
study of investigating biological activity of MIAT to the 
non-Hodgkin’s lymphoma cells. Although further study 
by applying different approach is needed to determine 
whether the anti-apoptotic function of MIAT is conserved 
Figure 6: Enforced suppression of MIAT or OCT4 in DB cells induces cell apoptosis. A. DB cells transfected with control 
siRNA or MIATsiRNA were assayed in biological triplicate for cell proliferation and Caspase 3/7 activities. B. DB cells infected with either 
control virus or OCT4shRNA harboring virus were assayed in biological triplicate for cell proliferation and Caspase 3/7 activities.
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in CLL, CLL cells are generally considered as low-grade 
non-Hodgkin lymphoma particularly in advanced stage. 
Therefore, we expect that the finding obtained from DB 
cells could be applicable to CLL cells. Upregulated MIAT 
may support monoclonal malignant B cell proliferation 
with naïve B-cell phenotype by evading cell apoptosis, and 
thus, contribute to disease progression. Similar function 
has been shown for CD38, a biomarker for disease 
progression of CLL [12]. CD38 is a trans-membrane 
molecule to drive CLL proliferation and chemotaxis via 
ZAP70-ERK1/2 signaling pathway [13]. Low linkage 
between MIAT expression level and CD38 or ZAP70 
status (see Figure 3A) indicates that actual molecular 
events leading to protect CLL cells from apoptosis are 
different between them. 
In summary, we showed that lncRNA MIAT is a 
potential new biomarker for aggressiveness of chronic 
lymphocytic leukemia and that MIAT functions to protect 
malignant mature B cells from cell apoptosis. 
MATERIALS AND METHODS
Patients
CLL samples were obtained from patients enrolled 
in the CLL Research Consortium and on written 
informed consent in accordance with the Declaration 
of Helsinki. The study protocols were approved by the 
Institutional Review Boards of The Ohio State University. 
The participating institutions provided the clinical 
data associated with each patient at the time of sample 
collection. The samples were analyzed to determine 
expression of ZAP70, CD38, immunoglobulin heavy chain 
variable mutational status and karyotype, as previously 
described [10]. 67 peripheral blood mononuclear cells 
(PBMC) were isolated by density gradient centrifugation 
with Ficoll-PaquePlus (Amersham Biosciences, Uppsala, 
Sweden).
Cell lines
A total of 38 leukemia/lymphoma cell lines were 
purchased either from the American Type Culture 
Collection (ATCC) or DSMZ (Deutsche Sammlung von 
Mikroorganismen und Zellkulturen, Germany). HEK-
293T cells derived from human embryonic kidney and 
transformed with SV40 large T antigen were obtained 
from Invitrogen (Carlsbad, CA, USA). All leukemic cell 
lines were cultured in RPMI 1640 supplemented with10% 
FBS and Penicillin/streptomycin. DLBL cell line, OCI-
LY-19 cells were cultured in α Minimal Essential Medium 
containing GlutaMAX™, supplemented with 20% FBS. 
HEK-293T cells were cultured in Dulbecco’s Modified 
Eagle’s Medium (DMEM) supplemented with 10% fetal 
bovine serum. Cells were maintained in a humidified 
incubator at 37°C and 5% CO2 and passaged every 2-3 
days. Early passaged (passage 4-7) cell lines were used for 
transfection or lentivirus infection experiment.
RNA extraction and real-time quantitative PCR
RNA from cultured cells and from patients with CLL 
was extracted with standard Trizol (Invitrogen) methods. 
Co-purified genomic DNA was removed by the treatment 
with DNase I (Thermo Fisher Scientific Inc., Amplification 
Grade, USA) according to the manufacturer’s instructions. 
RNA extracted from lentivirus infected cells was further 
purified by using RNA Clean Up and Concentration 
Kit (Norgen Biotek, Canada). 80 ng of total RNA was 
subjected to cDNA synthesis by using Super Script VILO 
DNA synthesis Kit (Invitrogen, USA) according to the 
manufacturer’s instructions. Real-time PCR analysis was 
carried out by using ABI PRISM 7900 Sequence Detection 
System. TaqMan® Gene Expression Assay Kits for the 
detection of MIAT, OCT4 and TBP were Hs00402814, 
4331182, and 433376, respectively (Life Technologies, 
USA). Assay was done in triplicates for each sample. The 
level of transcription was measured with Ct (threshold-
cycle). The amount of target, normalized to an endogenous 
reference, is given by 2−ΔCt (Comparative Ct method; 
Applied Biosystem).
Gene silencing by siRNA transfection and 
lentivirus-mediated transduction of shRNA
For silencing MIAT, smart pool of 4 siRNAs 
directed against MIAT, designed to target all variants of 
MIAT (NCBI accession no. NR_033321, NR_033320, 
NR_003491, NR_033319) was purchased from 
Dharmacon. 100nM of MIAT siRNAs were transfected 
into DB cells (5×105 cells in a well of 24 well plate) 
using Dharmafect transfection reagent (Dharmacon). 
For silencing OCT4, OCT4 shRNA Transfection Starter 
Kit (Dharmacon), composed of 4 shRNA constructs 
in pGIPZ vector and each targeting a unique region of 
OCT4 gene, was purchased. The pGIPZ construct was 
cotransfected with lentiviral packaging mix (Thermo 
Scientific, Cat# TLP5912) into HEK-293T cells according 
to the manufacturer’s instructions to generate lentivirus 
harboring shRNA against OCT4. Viral titer of approx. 
1 × 106 pfu/ml, titrated by counting GFP-transduced 
HEK293 cells (post-infection 48hr), could be obtained. 
Lentiviruses derived from 4 constructs were individually 
screened for their efficiencies of OCT4 suppression in 
HEK293T cells and the virus preparation from construct 
#41, which exhibited highest suppression was used for the 
subsequent studies. 1 × 105 DB cells were infected with 
the lentivirus (2 × 105 pfu, M.O.I.: 2) in a round-bottomed 
5 ml polypropylene tube (Falcon), adjusted to 0.5ml with 
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RPMI 1640 medium containing Polybrene (Sigma) at a 
concentration of 8μg/ml. Virus-host cell mixture in the 
tube was centrifuged at 2000 × g, for 3 hrs at RT, followed 
by an additional incubation for overnight at 37° (spin 
inoculation). Infected cells were washed, resuspended into 
0.5ml of RPMI 1640 medium containing 10% FBS, and 
cultured for 48 ~ 72 hrs in a well of 24 well culture plate.
Western blot analysis
Whole cell extracts were prepared from cells by 
adding RIPA lysis buffer (150mM NaCl, 0.1% SDS, 
0.5% sodium deoxycholate, 1% NP-40) (Sigma) with 
complete protease inhibitor cocktails (Sigma). Cell 
lyzate was centrifuged at 13000 rpm for 15 min at 4°C 
and the supernatant was collected. Protein concentration 
was determined by using Bradford reagent (Bio-Rad). 
30μg of protein was resolved in 4-15% Mini-PROTEAN 
TGX pre-cast gel (Bio-Rad), blotted onto a nitrocellulose 
membrane, and was probed with OCT4 antibody (Abcam 
ab19857) at a dilution of 1000. GAPDH detected on the 
same blot served as a loading control.
Cell proliferation assay
Cell proliferation was determined by using 
The CellTiter 96® AQueous One Solution kit (MTS) 
(Promega). 20μl of CellTiter 96® AQueous One Solution 
Reagent was added into each well of the 96-well assay 
plate where 8 × 103 cells in 100μl of culture medium 
were seeded. 1 hr after incubation at 37°C, 5% CO2, 
absorbance at 490nm was measured using a plate-reading 
illuminometer (infinite F200 PRO, Tecan Group). All of 
the experiments were performed in triplicate.
Caspase-Glo 3/7 cell apoptosis assay
Caspase-3/7 activity was assayed by adding 100μl 
of Caspase-Glo® 3/7 assay reagent (Promega) into each 
well of 96-well plate containing manipulated cells in 
100μl media. Readings of blank well and control treated 
cells were served as assay control. Luminescence of 
each sample was measured by using plate-reading 
illuminometer (infinite F200 PRO, Tecan Group Ltd).
Statistical analysis
Statistical significance was determined with two-
tailed student’s t-test by using GraphPad Prism 6.01. 
P-value of less than 0.05 was considered as significant. 
Confidence Level was at 95%.
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